CMV's Real World When Two Prophylaxis Studies Declare Opposite Findings, Clinicians And Their Patients Are Lost in the Quandary - A question of patient management
Giving Away the Farm How Corporate Cynicism, Savvy Schmoozing and Relentless PR Paved The Way to Unqualified Approval for Two New Antiretrovirals - "Grave disservice to the public health"
Random Gleanings Tracking down the elusive CD8 cell factor, FDA panel recommends approval for ganciclovir implant, FDA approval for saquinavir; Lottery for ritonavir
Antiretroviral Horizon 35th Interscience Conference Unveils Results from Several Important Clinical Studies - Protease and paradox
I'll Take Los Angeles AIDS Treatment Activists from Across the Land Gather to Share Expertise and Ideas - "A conversation long overdue"
Random Gleanings FDA Antiviral Drugs Advisory Committee, Ambushed in the FDCs, Expanding T cells: Koenig weighs in on Good CTLs/Bad CTLs debate
October, 1995
"Kiss My Access" Community Envoy to Food and Drug Panel Urges Caution in Approving New Anti-HIV Therapueutics and in Providing Early Access - "Badgering, hijacking activists"
Reversal of Fortune Despite Pressure to Crown Combo King, 175 Investigators Soft-Pedal Combination Nucleoside Study's Startling Findings - The didanosine surprise
Washington Woes Senate Appropriations Committee, the OAR's blue-ribbon review of the NIH AIDS program, TAG's Gregg Gonsalves, AmFAR Public Policy Director Jane Silver
Batten Down the Hatches House Republican Plan Calls for AIDS Research Dollars to Be Mixed Into Pot For All to Avail Themselves Of - The OAR as paper tiger
Combo Jumbo Controversial Nucleoside Study Awakens To A World Strangely Disaffected By Its Prepackaged Proclamation - Beware the Composite endpoint
Science South of the Border Feel Good Merck Meeting Leaves Everybody Agreeing, But Brazil Study Bodes Ill for the Future - Wrangling over control arm
Diversity Threshold New Model of Immune Defense to HIV Shows How Nature of Response Might Determine Eventual Outcome - Sloppy RT, Bane of All
April, 1995
Integrase: The Next Viral Target With Two Down And Integrase On Deck, AIDS Research Team Hopes For a Hit--Or Will It Be 'Three Up, Three Down?'
The Doxil NDA FDA's Oncological Drug Advisory Committee Recommends DOX-SL for Accelerated Approval--But Not Without A Fight
March, 1995
Random Gleanings FDA Just Says "No" To Salk Immunogen, Heralding the Naked Emperor (Part II), OAR's Dr. Paul Speaks, Varmus Selects New Director for Office of Alternative Medicine
Dr. Emini's Gamble Merck's Scientists Cave In To The Vogue of Surrogate Marker Endpoint Trials, Accelerated Approval And Quick Cash
Souped-Up Abs from LTNPs Inauspicious Debut for HIV Specific CTLs; New Concerns about IL-12; Neutralizing Approaches for "Bad" Cytokines; Parke-Davis Targets Cellular Factors
February, 1995
The CTL As Both Villain and Victor Fascinating Work on HIV and T-Cell Kinetics Challenges Longtime Dismissal of Ravaged Immune System's Regenerative Potential
Re-Inventing Government New ACTG Structure Squeezes Eleven Committees Into Three--But Will Anything Really Be Any Different?
Hope for Sale Like the Wings of Icarus, Treatment Hype Sweeps Its prey Upward to the Heavens, Then Plucks Them Down Into icey Waters
January, 1995
When Viral Load Is Crowned King With Good Intenntions, Over-Zealous Researchers May Be Setting the Stage For Yet Another Colossal Failure
Tyranny of the Minority What the New Republican Congress Will Mean for AIDS Prevention, Treatment and Research
E-Mail
Printable Single-Page
Glossary
Share
